Although no direct comparison was made between the use of anti-BCMA and the usual regimen of multiple myeloma, the regimen using rituximab, lenalidomide, and bendamustine showed a complete response rate of 64%, which was higher compared with anti-BCMA [32]. Here, TNFRSF17 is linked to AL amyloidosis.